In the past week, the scale of medical funds that have recently been set up was as high as RMB 6 billion. Under the economic crisis, the medical industry, which was characterized by its anti-cyclical nature, became a closely watched investment industry. The involvement of investment funds has quietly accelerated the pace of this investment. Turning nowadays, the world-famous A/H1N1 flu epidemic has once again made the development of vaccines and other industries the focus. Venture capitalists have stated that the epidemic will inevitably continue to increase investors’ attention to the industry and interviewed venture capitalists. They said that they all pay attention to bio-pharmaceutical projects, but the industry is "hard work" and cannot be accomplished overnight. New capital must have long-term plans. 6 Billion Medical Industry Fund to Be Available The information disclosed at the end of last month shows that CCB International's healthcare equity investment fund (hereinafter referred to as CCB Medical Fund) has obtained the approval document from the National Development and Reform Commission. This is the first approved RMB medical fund and is also the first Chinese company to focus on Invest in equity investment funds in the healthcare industry. Chen Chunliu, deputy director of marketing for Jianyin Medical Fund, recently stated that CCB Medical Fund is jointly managed by CCB International and Tongren Medical Industry Group. It is expected that the first phase of the fund will not exceed RMB 5 billion in the first seven years. In the last week before May Day, Bio Veda Capital, a world-renowned venture capital fund in the biomedical industry, was interested in setting up a joint venture in the Guangzhou Development Zone due to its optimistic outlook for the development of the Guangzhou biopharmaceutical industry. It is a billion-two billion yuan biomedical industry development fund. In just one week, the amount of medical funds disclosed exceeded RMB 6 billion, which is really exciting. In this regard, venture capitalists pointed out that the introduction of large-scale medical funds will directly benefit from the new medical reform program just launched by the country. “The enlistment of large-scale industrial funds in the medical industry is encouraging and will attract more capital to pay attention to the medical industry. However, from the current situation of the operation of some large-scale industrial funds, the effect remains to be seen.†Yesterday afternoon, Shenzhen Junsheng Investment Management Limited In an interview with the reporter, the president of the company, Liao Junjun, said that the issue of how to manage large-scale industrial funds is very important. “From the point of view of our investment projects, once idle funds are placed on our accounts, it will feel particularly stressful. Generally investing in a project requires investigating 20 to 30 projects, and the cost of management and operation is quite high,†said Liao Yijun. May create a heavyweight biopharmaceutical company After entering this round of economic crisis, the anti-cyclical industry represented by medicine has always been favored by venture capitalists. Research reports from brokerage companies show that the biopharmaceutical industry has broad prospects. On the 6th of last month, the new medical reform program was officially released. Last month, Li Qiushi, an industry researcher at the East Bank Securities Research Institute, pointed out in his report that China’s biotech R&D is being strengthened. We began to conduct research on biopharmaceutical companies that may be producing heavy products in China, pay attention to their R&D progress, and draw attention to treatment. Hepatitis B and AIDS vaccines, monoclonal antibodies, and recombinant human growth hormone and other industries. “We believe that the introduction of the official draft of the medical reform plan will speed up the medical improvement process, and the continued increase in government investment will fully release the pent-up demand for drugs in the next 3-5 years.†CIC Securities Industry Researcher pointed out the relevant plans for the new healthcare reform. The news shows that the CCB Medical Fund plans to invest in five key directions: the pharmaceutical industry (investment in new drugs, special drugs, and traditional Chinese medicine), medical devices (investment, leasing of medical devices, equipment), medical institutions (formation, renovation, management of hospitals, and idle rents Medical equipment), medical services (medical commercial logistics, electronic networks, training, tele-consultation) and rehabilitation health care. "Basically, these five directions cover all medical-related industries. Only the general medicine category is involved." Yesterday afternoon, Shenzhen, a venture capital company CEO told reporters that the general pharmaceutical industry because of meager profits, I am afraid it is difficult to become a venture capital The focus of attention. However, in Liao Yujun's view, the country's new medical reform scheme has reduced circulation costs, and the overall profits of generic pharmaceutical products have actually been magnified. “In the past, rural areas used mostly drugs that were eliminated. The universal health insurance plan covers 80% of the market including rural areas for three to five years, so that the entire amount of drugs is greatly increased and the market prospect is very broad,†said Liao Yujun. Epidemic Situation, Venture Capital Accelerates Investment In the interview process, a number of venture capitalists stated that with the spread of the major epidemic of the H1N1 flu, venture capitalists will focus more on the medical industry and the pace of investment will increase accordingly. Huang Wei, the president of Shenzhen High-tech Investment Group Co., Ltd., which has always focused on bio-pharmaceuticals, said that the company is currently preparing to invest in some vaccine companies. “Recently we have been watching vaccine companies. The companies we invested in before and the vaccine companies belong to the upstream and downstream relationship. The vaccine will be an investment focus for our company in the future,†said Huang Wei. His company began to enter the biopharmaceutical industry through the equity participation of Hunan Jingda Bioengineering Co., Ltd. at the end of 2006, and it further expanded its field and share in the industry by controlling Boya Biopharmaceuticals Co., Ltd. at the end of 2007. Liao Yujun said that the company is currently following up on vaccine projects. "HIV and HBV vaccines are currently mainly imported from abroad. If there are domestic companies that produce such drugs, the overall cost will be greatly reduced." Liao Yujun said that similar vaccines that closely related to women's health, such as the female cervical cancer vaccine, Whether it is introduced or produced by domestic companies remains to be resolved. "The new vaccine development will take too long and China will not lag behind in terms of biopharmaceutical technology. However, the vaccine is relatively weak and there is a huge market space," said Liao Yujun. “However, this is a very difficult industry and it cannot be done overnight. New capital must have long-term plans. It cannot be flocked just because of the arrival of the H1N1 flu.†Huang Xin reminded. Jiangsu Bestech Industrial Co., Ltd. , https://www.jsbestmachine.com